56 results about "CD86" patented technology

The invention relates to the field of cell biology, and particularly relates to a preparation method of a pancreatic cancer-related antigen-loaded polypeptide, which is characterized in that factors such as GM-CSF, IL-4, IFN-gamma, TNF-alpha, IL-1beta, IL-6, PGE2, Poly I: C, R848 and the like are added to promote mononuclear cells to be activated into DC cells, pancreatic cancer PANC-1, MIA PaCa-2, BxPC-3, KP4 and SW1990HM antigens are loaded, and not only is DC cell maturation promoted, but also pancreatic cancer-related antigens are loaded. The positive rate of CD83 + CD86 of the DC cells cultured by the method is 94.16%, and the secretion amount of IL-12p70 in a cell supernatant is (645.38 + / -36.49) pg / mL. By adopting the culture method disclosed by the invention, the maturation rate of the DC cells can be improved while the DC cells are activated, so that the culture method for promoting the maturation and amplification of the DC cells loaded with the pancreatic cancer antigen is achieved.

To provide an allogeneic tumor cell vaccine.SOLUTION: Provided is an allogeneic tumor cell vaccine, comprising: (1) a population of proliferation-incompetent, live, genetically engineered tumor cells expressing one or more tumor-specific antigens, the population comprising at least three stably expressed immunomodulatory molecules, at least three immunomodulatory molecules being OX40 ligand (OX40L), CD27 ligand (CD70), and CD28 ligand (CD28L) including CD80, CD86, or both, to induce one or more subpopulations of PBMCs to proliferate in response to the expressed immunomodulatory molecules and subsequently enter an effector phase to kill tumor cells, and the subpopulations of PBMC cells comprising one or more of T lymphocytes, natural killer (NK) cells, dendritic cells (DCs), or B lymphocytes; and (2) a pharmaceutically acceptable carrier.SELECTED DRAWING: None

The invention belongs to the technical field of vaccines, and particularly relates to a manganese-based platelet carrier vaccine based on a biomimetic mineralization technology and application of the manganese-based platelet carrier vaccine in immunotherapy. A manganese-based shell is deposited on the surface of a platelet, immunocompetence molecules such as CD40L and PF4 are expressed on the surface of the platelet, dendritic cells (DC) can be activated by directly contacting or secreting cell factors, and antigen presentation is promoted; in addition, deposited manganese ions can activate a cGAS-STING pathway, and meanwhile, CD40 / CD80 / CD86 / MHC-II costimulatory molecular expression on the surface of the DC is up-regulated. The vaccine adjuvant provided by the invention can be used for loading an antigen to form a three-in-one vaccine complex of the antigen (loaded on a platelet membrane), the platelet and a manganese shell, so that not only is the natural targeting capability of the platelet retained, but also DC cross presentation is enhanced through continuous release of manganese ions, finally CD8 + T cells are synergistically activated to react with an antibody, and the immune response of the antigen is enhanced. The antiviral immune response of the body is enhanced.

The invention relates to the technical field of cellular immunotherapy, in particular to application of drafenib mesylate in preparation of a dendritic cell (DCs) immunologic adjuvant. The invention provides an application of drafenib mesylate in preparation of a dendritic cell immunologic adjuvant. It is found that darfenib mesylate can promote the maturation and migration functions of DCs, and the migration ability of DCs is remarkably improved. The DCs activation aspect of the darfenib mesylate comprises improvement of expression of maturation indexes CD80, CD40 and CD86 and expression of a migration index CCR7. Darrafenib mesylate used in the invention is a chemotherapeutic drug approved by FDA for clinical treatment of patients with BRAF V600 mutation positive non-resectable or metastatic melanoma, the application of Darrafenib mesylate in immunotherapy is discovered, new use of old drugs is realized, and the Darrafenib mesylate has significant economic value.

The invention discloses a polypeptide with tumor cell killing activity. The specific molecular target or the fusion polypeptide thereof is co-cultured with autoimmune cells of a subject, and then the autoimmune cells are transfused back into the body of the subject, so that targeted killing of tumor cells is realized, and the purpose of treating tumors is achieved. The dendritic cell (DC) load positive rate activated by the molecular target is greater than 90%. Furthermore, the activated DC cells highly express CD80 and CD86 on the surface, and can effectively present tumor antigens to T lymphocytes, thereby inducing to generate CTL cells with the capability of specifically recognizing cancer cells.

The invention relates to application of beta-glucan in preparation of a preparation for reducing the expression quantity of related genes of skin extracellular matrix inflammation. The structure of the beta-glucan is formed by connecting structural units. The invention also provides a biomarker, the biomarker is a gene related to skin extracellular matrix inflammation, and the gene comprises any one or a combination of at least two of IL1A, IL1B, IL1R1, IL1RAP, IL6, NFKB2, FOSB, FOSL1, JUN, JUND, CCL2, PTGS2, MMP10, MMP12, MMP13, CXCL8, CD86, PLAU, GADD45A, TNFSF18, TNFRSF10B, TNFRSF12A, TNFRSF14 or TNFRSF21.

The application discloses an antigen-engineered nanovesicle vaccine (AN-FV) and a preparation method and application thereof. The vaccine is formed by fusion of vesicles of tumor cell membranes obtained by pretreatment of functionalized nanometer preparations and vesicles of mature dendritic cell membranes; the functionalized nanometer preparations contain autophagy inhibiting siRNA and an immunogenicity enhancer, and can synergistically improve MHC-I expression of tumor cells and antigen immunogenicity. The vaccine of the application simultaneously presents high-density MHC-I-antigen peptide complexes and CD80 / CD86 costimulatory molecules on the surface of a single particle, simulates an immune synapse in a nanometer scale, and thus efficiently activates tumor-specific T cells. The vaccine integrates antigen source engineering, physiologicalization of costimulatory signals and nanometer platform integration, and provides a new scheme for overcoming the treatment bottleneck of immune "cold" tumors such as pancreatic cancer.

The invention belongs to the technical field of biological medicines, and particularly relates to application of crizotinib in induction of tolerant dendritic cells (tDCs). The invention provides an application of crizotinib in induction of tolerant dendritic cells. It is found that crizotinib can serve as an efficient inducer of tDCs, the activation state of DCs can be remarkably inhibited, the maturation function of DCs can be inhibited, the immune stimulation capacity of DCs can be reduced, then activation of T cells is inhibited, and therefore the crizotinib plays a role in treating immune diseases such as GVHD. In the invention, the inhibition of crizotinib on DCs comprises reduction of expression of maturation indexes CD80, CD40 and CD86. The crizotinib used in the invention is an ALK / ROS1 inhibitor approved by FDA and is mainly used for treating non-small cell lung cancer, the application of the crizotinib in immunotherapy is found, new use of old medicines is realized, and the crizotinib has great economic value.

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

The application relates to the field of biological medicines, and discloses a tumor vaccine containing a polysaccharide adjuvant and application thereof. The tumor vaccine formula comprises, in terms of mass fractions, 100 parts of WT1-CM-betaG NPs, 10 parts of astragalus polysaccharide, 5 parts of quillaja saponin and 1 part of a TLR agonist. The WT1-CM-betaG NPs comprise, in terms of mass fractions, 10 parts of a WT1 polypeptide combination, 50 parts of carboxymethylated beta-glucan nanoparticles CM-betaG NPs, 10 parts of EDC and 6 parts of NHS. The WT1 polypeptide is covalently connected to the carboxymethylated beta-glucan nanoparticles through chemical coupling, and then cooperates with the adjuvant, has a synergistic effect on improving the ability of stimulating DC maturation (high expression of CD80 / CD86 / MHC-II) and improving the secretion of key Th1 type cytokine IL-12p70, can improve the antitumor effect, and has a wide application in treating WT1 positive tumors.

The invention relates to the field of biological medicine, and discloses a tumor vaccine containing a polysaccharide adjuvant and application of the tumor vaccine, and the tumor vaccine is prepared from, by mass, 100 parts of WT1-CM-beta G NPs, 10 parts of astragalus polysaccharide, 5 parts of saponin and 1 part of TLR agonist. The WT1-CM-beta G NPs is prepared from the following components in parts by mass: 10 parts of a WT1 polypeptide combination, 50 parts of carboxymethylated beta-glucan nano CM-beta G NPs, 10 parts of EDC (Ethylene Dichloride) and 6 parts of NHS (N-Hydroxysuccinimide). The WT1 polypeptide is covalently linked to the carboxymethylated beta-glucan nanoparticles through chemical coupling, then the WT1 polypeptide and the carboxymethylated beta-glucan nanoparticles cooperate with the adjuvant, the WT1 polypeptide and the carboxymethylated beta-glucan nanoparticles have a synergistic effect on improving the capability of stimulating DC maturation (highly expressing CD80 / CD86 / MHC-II) and improving the secretion of key Th1 type cell factors IL-12p70, can improve the anti-tumor effect, and have wide application in treating WT1 positive tumors.

Provided herein are particles containing a fusion molecule comprising an adhesion molecule linked to a costimulatory molecule or an activation molecule, as well as vectors such as lentiviral vectors containing the same, cells containing the same, and methods for using the same. The particle may be a lentiviral particle that displays a fusion molecule containing a) the CD58 extracellular domain or a functional fragment thereof, b) an antigen-binding fragment of an anti-CD3 antibody, and c) the CD80 or CD86 extracellular domain or a functional fragment thereof, and a viral glycoprotein (G protein) on the surface of the particle.

This invention belongs to the field of biomedical technology, specifically relating to the application of crizotinib in inducing tolerant dendritic cells (tDCs). This invention provides the application of crizotinib in inducing tolerant dendritic cells. This invention discovers that crizotinib can act as a highly effective inducer of tDCs, significantly inhibiting the activated state of DCs, suppressing their maturation function, reducing their immunostimulatory capacity, and thus inhibiting T cell activation, thereby exerting a therapeutic effect in immune diseases such as GVHD. The inhibitory effects of crizotinib on DCs in this invention include reducing the expression of maturation markers CD80, CD40, and CD86. The crizotinib used in this invention is an FDA-approved ALK / ROS1 inhibitor, primarily used for the treatment of non-small cell lung cancer. This invention discovers its application in immunotherapy, realizing the repurposing of an existing drug, and has significant economic value.

The application relates to the field of immunology, and provides an application of silk sericin and silk polypeptide, researches on extraction and purification methods of silk sericin and polypeptide, finds that the protein and polypeptide can promote maturation of dendritic cells, enhance expression of MHCII and CD86 on the cell surface, enhance antigen presentation capacity, and stimulate lymphocyte T cell proliferation in cooperation with the dendritic cells; researches on a preparation method of nanoemulsion vaccine prepared by taking the silk sericin and polypeptide as an adjuvant and antigens, and detection finds that the silk sericin and polypeptide can improve the immune activation efficiency of the vaccine, obviously enhance the antigen-specific acquired immune response level in the body, and effectively inhibit the virus infection of the body and the replication level of the virus, so that the purpose of enhancing the vaccine in preventing or treating diseases is achieved.

This invention provides a method for screening peptides that specifically target T cells, comprising providing T cells having a subset selected from CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L) The T cells are labeled with at least one of the following surface antigen markers: CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7. The T cells are then contacted with a peptide display library, and target peptides that specifically bind to the T cells are screened therefrom.

CD38 is expressed on malignant plasma cells. CD28 is a costimulatory molecule required for T-cell activation and survival. Provided herein are novel anti-CD38 antibodies, anti-CD28 antibodies, and bispecific antibodies (bsAbs) that bind to both CD38 and CD28 and act as costimulatory agents to activate T cells via binding CD80 and / or CD86. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD38. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced CD38-targeted immune response is desired and / or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma, lymphoma, and leukemia.

The present invention relates to the field of biomedicine. Provided are a monoclonal antibody targeting human HHLA2, and a multifunctional fusion antibody molecule derived therefrom. The HLLA2 monoclonal antibody can bind to an HLLA2 antigen with high specificity, and effectively block an immunosuppressive signaling pathway between the antigen and a receptor KIR3DL3, thereby relieving the functional inhibition of T cells and enhancing the tumor-killing function of NK cells. On the basis of the antibody scaffold, a fusion antibody comprising a plurality of immunomodulatory domains is constructed, wherein the domains comprise, but are not limited to, an anti-PD-L1 antibody or anti-PD-1 antibody or anti-CD3 antibody domain, a CD86 / CD80 variant polypeptide, and an LAG3 variant polypeptide. The fusion antibody can synergistically block a plurality of immune checkpoint pathways, activate costimulatory signals, promote maturation of antigen-presenting cells, and enhance activation and killing functions of T cells. The provided antibody molecule can be used for preparing immunotherapy drugs for a variety of indications, is especially suitable for the treatment of solid tumors or hematologic tumors, and thus has significant application potential in terms of enhancing anti-tumor immune responses.

In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a U937 cell modified to express one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. Further provided are lipid nanoparticles (LNPs) conjugated to one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs or LNPs and methods of treating cancers using TILs after expansion with aAPCs or LNPs are also disclosed.

Provided is a method for screening polypeptides that specifically target T cells, comprising: providing T cells having a surface antigen marker selected from at least one of CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L), CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7; and contacting the T cells with a polypeptide display library, and screening therefrom target polypeptides that specifically bind to the T cells.

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

The application discloses a PGPC / CpG combined adjuvant and a method and application thereof for improving the efficiency of a type I dendritic cell anti-tumor vaccine, and belongs to the technical field of biotechnology. The method for improving the efficiency of the type I dendritic cell anti-tumor vaccine by using the PGPC / CpG combined adjuvant disclosed by the application stimulates cDC1 by using the PGPC / CpG combined adjuvant; the final concentration of the CpG is 1 mM, and the final concentration of the PGPC is 25 µg / mL. The PGPC / CpG combined adjuvant can significantly promote the expression of the co-stimulating molecules CD40, CD80, CD86 on the surface of cDC1, and inflammatory factors IL-12, TNFɑ and IL-1β, enhance the ability of the cDC1 to induce CD8 + T cell activation, proliferation and differentiation into anti-tumor effector T cells, and effectively improve the in-vivo anti-tumor effect of the cDC1 vaccine.

In some embodiments, compositions and methods re¬lating to isolated artificial antigen presenting cells (aAPCs) are dis¬closed, including aAPCs comprising a myeloid cell transduced with one or more viral vectors, such as a MOLM-14 or a EM-3 myeloid cell, wherein the myeloid cell endogenously expresses HLA-A / B / C, ICOS-L, and CD58, and wherein the one or more viral vectors com¬prise a nucleic acid encoding CD86 and a nucleic acid encoding 4-1BBL and / or OX40L and transduce the myeloid cell to express CD86 and 4-1BBL and / or OX40L proteins. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs and methods of treating cancers using TILs after expansion with aAPCs are also disclosed.

The present disclosure provides a novel technique relating to immunological tolerance. More specifically, the present inventor found for the first time that, in a technique for inducing immunological tolerance by administering to an organ transplantation patient (a recipient) a cell preparation containing cells in which anergy is induced by an inhibitor inhibiting the interaction between CD80 / CD86 and CD28, the immunological tolerance continues even after the disappearance of the cells derived from the cell preparation from the recipient (infectious immunological tolerance). Further, the present inventor proved that such a cell preparation can elicit immunological tolerance against immunological rejection caused by allergy, iPS cells, etc. or cells, tissues or organs derived therefrom.

Described herein is a method of isolating or enriching a population of cells for IL-10 producing type 2 innate lymphocytes, the method comprising: providing a population of cells comprising ILC2; cells expressing at least one of the following three markers: CD86, CD49d and retinoic acid related orphan alpha (RORA) are selected, and / or cells expressing GATA3 are rejected, including kits for implementing the methods. The use of isolated or enriched cell populations for cell therapy is also provided.

In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a U937 cell modified to express one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. Further provided are lipid nanoparticles (LNPs) conjugated to one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs or LNPs and methods of treating cancers using TILs after expansion with aAPCs or LNPs are also disclosed.